安必平(688393.SH):並未參與瑞金病理大模型的研究與開發
格隆匯2月17日丨安必平(688393.SH)公佈,公司並未參與瑞金病理大模型的研究與開發。公司於2022年5月與華爲技術有限公司簽署《基於昇騰AI硬件平臺的組織學病理診斷合同備忘錄》,合作意向內容包括探索病理影像原生可信AI與可解釋AI技術。截至本公告披露日,雙方合作並未形成具體產品。
公司於2020年8月與騰訊科技(深圳)有限公司簽訂戰略合作協議,合作內容爲“人工智能技術在顯微影像分析儀中的應用:人工智能宮頸脫落細胞(安必平沉降式LBP)識別算法”。目前該產品已經獲得二類醫療器械產品註冊證,2024年度,該產品直接銷售收入佔營業收入比例不足0.50%。該產品尚未獲得三類醫療器械註冊證,獲證以及後續實際銷售情況具有不確定性。截至本公告披露日,公司與騰訊科技(深圳)有限公司不存在其他腫瘤篩查或診斷相關的人工智能輔助產品的開發合作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.